ABUS vs. CMPS, ATXS, APLT, LRMR, VERV, CDMO, ALT, KALV, TVTX, and OCS
Should you be buying Arbutus Biopharma stock or one of its competitors? The main competitors of Arbutus Biopharma include COMPASS Pathways (CMPS), Astria Therapeutics (ATXS), Applied Therapeutics (APLT), Larimar Therapeutics (LRMR), Verve Therapeutics (VERV), Avid Bioservices (CDMO), Altimmune (ALT), KalVista Pharmaceuticals (KALV), Travere Therapeutics (TVTX), and Oculis (OCS). These companies are all part of the "pharmaceutical preparations" industry.
Arbutus Biopharma (NASDAQ:ABUS) and COMPASS Pathways (NASDAQ:CMPS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, community ranking, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.
COMPASS Pathways has a net margin of 0.00% compared to Arbutus Biopharma's net margin of -572.81%. COMPASS Pathways' return on equity of -58.72% beat Arbutus Biopharma's return on equity.
Arbutus Biopharma presently has a consensus price target of $4.33, indicating a potential upside of 47.39%. COMPASS Pathways has a consensus price target of $47.40, indicating a potential upside of 455.04%. Given COMPASS Pathways' higher possible upside, analysts plainly believe COMPASS Pathways is more favorable than Arbutus Biopharma.
43.8% of Arbutus Biopharma shares are held by institutional investors. Comparatively, 46.2% of COMPASS Pathways shares are held by institutional investors. 4.0% of Arbutus Biopharma shares are held by company insiders. Comparatively, 4.3% of COMPASS Pathways shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Arbutus Biopharma has higher revenue and earnings than COMPASS Pathways. Arbutus Biopharma is trading at a lower price-to-earnings ratio than COMPASS Pathways, indicating that it is currently the more affordable of the two stocks.
Arbutus Biopharma received 376 more outperform votes than COMPASS Pathways when rated by MarketBeat users. However, 76.56% of users gave COMPASS Pathways an outperform vote while only 70.83% of users gave Arbutus Biopharma an outperform vote.
Arbutus Biopharma has a beta of 2.05, suggesting that its share price is 105% more volatile than the S&P 500. Comparatively, COMPASS Pathways has a beta of 2.39, suggesting that its share price is 139% more volatile than the S&P 500.
In the previous week, Arbutus Biopharma had 1 more articles in the media than COMPASS Pathways. MarketBeat recorded 11 mentions for Arbutus Biopharma and 10 mentions for COMPASS Pathways. Arbutus Biopharma's average media sentiment score of 0.29 beat COMPASS Pathways' score of 0.01 indicating that Arbutus Biopharma is being referred to more favorably in the media.
Summary
COMPASS Pathways beats Arbutus Biopharma on 9 of the 16 factors compared between the two stocks.
Get Arbutus Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ABUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Arbutus Biopharma Competitors List
Related Companies and Tools
